CSIMarket Company Name, Ticker, Customers, else..
 
Renovorx Inc   (NASDAQ: RNXT)
 
Price: $2.3900 $0.02 0.844%
Day's High: $2.539599895477295 Week Perf: 23.83 %
Day's Low: $ 2.28 30 Day Perf: 107.83 %
Volume (M): 2,084,116 52 Wk High: $ 2.59
Volume (M$): $ 0 52 Wk Avg: $1.02
Open: $2.35 52 Wk Low: $0.70



 Market Capitalization (Millions $) 113
 Shares Outstanding (Millions) 47
 Employees 17
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) 2
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Renovorx Inc is a medical technology company that develops innovative solutions for the treatment of cardiovascular diseases. The company specializes in developing catheter-based therapies, such as drug-coated balloons and stents, to address various cardiovascular conditions, including peripheral artery disease and coronary artery disease. Renovorx Inc aims to improve patient outcomes by providing minimally invasive and effective treatment options. Through its cutting-edge technologies, the company strives to revolutionize the field of cardiovascular interventions and enhance the quality of life for patients.


   Company Address: 2570 West El Camino Rea Mountain View 94040 CA
   Company Phone Number: 284-4433   Stock Exchange / Ticker: NASDAQ RNXT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        2.68% 
MRK        1.33% 
PFE        1.75% 
TEVA   -0.22%    
VRTX        0.82% 
VTRS        3.3% 
• View Complete Report
   



Business Update

Balancing Breakthroughs and Bottom Lines RenovoRx Shines at SSO 2025 Despite Economic Challenges,

Published Sat, Mar 29 2025 8:52 AM UTC

RenovoRx Unveils Promising Pharmacokinetic Data Amidst Challenging Market Conditions RenovoRx, a life sciences company known for its targeted oncology therapies, has taken a notable step forward by presenting new human pharmacokinetic (PK) data at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. This event, held from March 27 to 29 in Tampa, Florida, served as a p...
Business Update

RenovoRx Unveils Groundbreaking Pre-Clinical Data at SSO 2025 A New Frontier in Targeted Cancer Therapy,

Published Wed, Mar 19 2025 12:48 PM UTC

In an important development for cancer treatment, RenovoRx, Inc. (Nasdaq: RNXT) a pioneering life sciences firm announced the upcoming presentation of groundbreaking pre-clinical data at the Society of Surgical Oncology (SSO) 2025 Annual Meeting. The event, scheduled for March 18-21, 2025, will serve as a platform for medical professionals, researchers, and industry stakehol...
Business Update

In a rapidly evolving landscape of oncology treatments, RenovoRx, Inc. (Nasdaq RNXT) stands at the forefron...

Published Tue, Dec 31 2024 8:51 AM UTC

Revolutionizing Cancer Care: RenovoRx s Expanding Intellectual Property Portfolio and Innovative Drug-Delivery Solutions In a rapidly evolving landscape of oncology treatments, RenovoRx, Inc. (Nasdaq: RNXT) stands at the forefront, pioneering novel therapeutic approaches with its groundbreaking drug-delivery system RenovoCath. Headquartered in Mountain View, California, th...
Business Update

Driving Innovation in Oncology RenovoRx Expands Intellectual Property and Prepares for 2025 Advancements

Published Mon, Dec 30 2024 5:04 PM UTC

In the ever-evolving landscape of oncology therapeutics, RenovoRx, Inc. stands at the forefront with its groundbreaking drug-delivery therapy platform, RenovoCath. The Mountain View-based life sciences company is not only committed to developing novel targeted cancer therapies but also safeguarding its innovations through a robust intellectual property (IP) portfolio. As Ren...
Product Service News

Comparing Performance and Prospects RenovoRx Inc. in the Context of Ongoing Innovation and Revenue Challenges in Onco...

Published Wed, Dec 11 2024 1:01 PM UTC

RenovoRx Inc. has recently made significant strides in the clinical landscape of oncology with the initiation of patient enrollment in its pivotal Phase III clinical trial, TIGeR-PaC, aimed at evaluating the Trans-Arterial Micro-Perfusion (TAMP) therapy platform. This groundbreaking trial, taking place at SCRI Oncology Partners, focuses on the treatment of locally advanced p...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 57.21
Price to Sales (Expected) -
Price to Book 12.59
PEG (TTM) -

Financial Strength Current
Quick Ratio 9.86
Working Capital Ratio 10.49
Leverage Ratio (MRQ) 0.28
Total Debt to Equity -
Interest Coverage (TTM) 17.48
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.31 $
Revenues (TTM) 0.04 $
Cash Flow (TTM) 0 $
Cash 0.39 $
Book Value 0.19 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 116,235
Net Income per Employee (TTM) 141,412
Receivable Turnover Ratio (TTM) 7.4
Inventory Turnover Ratio (TTM) 1.01
Asset Turnover Ratio (TTM) 0.15

Profitability Ratios Current
Gross Margin (MRQ) 84.27 %
Operating Margin (MRQ) -368.43 %
Net Margin (MRQ) -320.24 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 17.91 %
Return On Investment (TTM) 25.93 %
Return On Equity (TTM) 28.5 %
Dividend Yield -
Pay out Ratio (TTM) -



Renovorx Inc's Segments
Other Segment    161.94 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.